Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.04M 13.72B 50.78M | Sales 2025 * | 41.12M 15.23B 56.38M | Capitalization | 226M 83.6B 309M |
---|---|---|---|---|---|
Net income 2024 * | -4M -1.48B -5.48M | Net income 2025 * | -1M -371M -1.37M | EV / Sales 2024 * | 6.09 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.49 x |
P/E ratio 2024 * |
-50.4
x | P/E ratio 2025 * |
504
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
1st Jan change | Capi. | |
---|---|---|
+48.21% | 58.71B | |
-3.01% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.44% | 26.55B | |
-23.20% | 18.98B | |
+1.92% | 12.51B | |
+25.80% | 12.08B | |
+21.89% | 11.94B |